Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.

Antimicrobial agents and chemotherapy - 1 Dec 2006

Margot N A, Waters J M, Miller M D

Abstract excerpt

Human immunodeficiency virus type 1 (HIV-1) resistance development was evaluated in vitro by using combinations of the drugs tenofovir and emtricitabine or abacavir and lamivudine, as well as by using the compounds individually. Emtricitabine- and lamivudine-resistant HIV-1 isolates with the M184I or M184V mutation in reverse transcriptase were readily selected in the cultures with emtricitabine alone, lamivudine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Deoxycytidine
Share to Dideoxynucleosides

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Multiple, Viral

Share to Emtricitabine

Share to Lamivudine

Share to Organophosphonates

Share to Tenofovir

Source

Open in PubMed Open full text

Identifiers

PMID: 16982781
DOI: 10.1128/AAC.00816-06
PMCID: PMC1693985

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.PMID 16982781Read ↗

Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.Semantic proximity Read ↗

Viral resistance and the selection of antiretroviral combinations.Semantic proximity Read ↗

Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors.Semantic proximity Read ↗

Tenofovir resistance and resensitization.Semantic proximity Read ↗

Evolution of tenofovir-resistant HIV-1 isolates exposed to tenofovir alafenamide dose escalation.Semantic proximity Read ↗

Different Evolution of Genotypic Resistance Profiles to Emtricitabine Versus Lamivudine in Tenofovir-Containing RegimensSemantic proximity Read ↗

Nucleoside and nucleotide analogs select in culture for different patterns of drug resistance in human immunodeficiency virus types 1 and 2.Semantic proximity Read ↗

Competitive capacity of HIV-1 strains carrying M184I or Y181I drug-resistant mutations.Semantic proximity Read ↗

In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine.Semantic proximity Read ↗

Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors.Semantic proximity Read ↗

Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimensSemantic proximity Read ↗

Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.